Immutep Initiates Phase III Trial for Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Source: Business Insider
Immutep Ltd Update: Immutep Limited has initiated the TACTI-004 Phase III trial to evaluate its LAG-3 immunotherapy, eftilagimod alfa, in combination with KEYTRUDA and chemotherapy for metastatic non-small cell lung cancer, aiming for patient enrollment by early 2025.
Significance of Trial: This trial represents a crucial advancement for Immutep in the biotech industry, potentially establishing a new standard of care for this type of cancer following approvals from Australia and expected global clearances.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
